Search

Discusses tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL), a possible anticancer drug developed by Genetech and Immunex. Indication that the compound can cause liver damage as found in a study published in `Nature Medicine'; Safety profile of TRAIL; Details of the study by Stephen Strom and colleagues at the University of Pittsburg in Pennsylvania; Implications of Strom's findings.

Focuses on a study revealing that the outcome for people with diabetes and multivessel coronary-artery disease is better after myocardial infarction. Advantage they have if they have previously undergone coronary-artery bypass grafting (CABG) rather than percutaneous transluminal coronary angioplasty (PTCA); Details of the research of Katherine Detre and colleagues at the University of Pittsburgh in Pennsylvania; Speculation on the difference in mortality; Assertion that CABG should be the treatment of choice.